New Results

Evidence for a Potential Pre-Pandemic SARS-like Coronavirus Among Animals in North America

Trevor J. Hancock, Peyton Hickman, Niloo Kazerooni, Melissa Kennedy, Stephen A. Kania, Michelle Dennis, Nicole Szafranski, Richard Gerhold, Chunlei Su, Tom Masi, Stephen Smith, Tim E. Sparer
doi: https://doi.org/10.1101/2021.12.17.473265

Abstract

In late 2019, a novel coronavirus began circulating within humans in central China. It was designated SARS-CoV-2 because of its genetic similarities to the 2003 SARS coronavirus (SARS-CoV). Now that SARS-CoV-2 has spread worldwide, there is a risk of it establishing new animal reservoirs and recombination with native circulating coronaviruses. To screen local animal populations in the United States for exposure to SARS-like coronaviruses, we developed a serological assay using the receptor binding domain (RBD) from SARS-CoV-2. SARS-CoV-2’s RBD differs from common human and animal coronaviruses allowing us to identify animals previously infected with SARS-CoV or SARS-CoV-2. Using an indirect ELISA for SARS-CoV-2’s RBD, we screened serum from wild and domestic animals for the presence of antibodies against SARS-CoV-2’s RBD. Surprisingly pre-pandemic feline serum samples submitted to the University of Tennessee Veterinary Hospital were ∼70% positive for anti-SARS RBD antibodies. This was independent of prior infection with a feline coronavirus (FCoV), eliminating the possibility of FCoV cross-reactivity. We also identified several white-tailed deer from South Carolina that were also positive for anti-SARS-CoV-2 antibodies. These results bring up an intriguing possibility of a circulating agent (likely a coronavirus) with enough similarity to the SARS RBD to generate cross-reactive antibodies. Finding seropositive cats and white-tailed deer prior to the current SARS-CoV-2 pandemic, further highlights our lack of information about circulating coronaviruses in other species.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent zoonotic beta-coronavirus initially discovered in late 2019 after human-to-human transmission within central China [1]. By early 2020, the virus had rapidly spread into a pandemic infecting millions of people and continues to circulate throughout the world. Like other human coronaviruses it is spread via aerosolized particles, causing respiratory infections [1, 2]. Infected individuals develop a range of symptoms from mild/asymptomatic infection to severe pneumonia-like disease (i.e., coronavirus disease (COVID)) [2]. Sequence analysis of known SARS coronaviruses points to a bat origin with probable intermediate hosts prior to human infection [3-5]. However, the exact intermediate host and factors that led to its zoonosis and establishment within humans are under investigation.

Secretion of SARS-CoV-2 is thought to be primarily via aerosolized particles with high viral loads in the lungs and nasopharyngeal secretions of infected individuals [6, 7]. However, both viral RNA and infectious particles have been detected in fecal samples of acutely infected individuals. In the original SARS-CoV outbreak, there was documented fecal-oral transmission of infection [6, 8-12]. Fecal to oral spread and shedding is a common route of transmission of other animal coronaviruses. Oropharyngeal viral RNA shedding of SARS-CoV-2 in humans lasts for ∼17 days on average but persists up to 60-120 days in the respiratory tract and stool [13]. Similarly, oropharyngeal secretion of infectious SARS-CoV-2 in cats appears to cease by 5-10 days post infection (dpi) [14]. Infected felids shed SARS-CoV-2 viral RNA in their feces for at least 5 dpi, but whether that represents infectious virus or a potential route of transmission is yet to be demonstrated [15].

Due to the multiple routes of spread and close contact with other species, transmission of SARS-CoV-2 from humans to animals is plausible [16]. Companion animals such as cats and dogs are susceptible to experimental as well as natural infection from COVID-positive owners [14, 17-21]. In addition, susceptible animals are capable of transmitting infection to cohoused animals [14, 22]. Human-to-animal and animal-to-animal transmission of SARS-CoV-2 has been documented or experimentally demonstrated. In the case of minks, transmission from humans-to-minks and back to humans was recently demonstrated [23]. Aside from the likely initial animal-to-human transmission and transmission from commercially maintained minks, there have been no further reports of zoonosis despite transmission into animal populations. This is in contrast to the Amoy Garden complex where animal-to-human transmission occurred even after the initial SARS-CoV outbreak when an animal vector potentially contracted and spread the infection throughout the complex [24-26]. Despite the lack of additional evidence for continued animal-to-human transmission, humans are transmitting SARS-CoV-2 to companion animals, opening up potential spillover into wild animal populations. This could contribute to the spread of SARS-like coronaviruses and the establishment of new reservoirs for recombination and the generation of future novel coronavirus outbreaks.

Infected humans and animals mount humoral responses to SARS-CoV-2 [13, 14, 27-29]. In humans, SARS-CoV-2 antibodies arise within 5-14 days post-infection/symptom onset and peak around 17-20 dpi [13, 28, 30]. For cats experimentally inoculated or naturally exposed to SARS-CoV-2, detectable antibody titers appeared by 7-14 days post-infection peaking ∼21 dpi [14]. This matches anti-FCoV responses where high antibody levels can arise within ∼9 dpi [31-33]. Immunity to coronaviruses in cats is typically short-lived, with the average FCoV humoral responses lasting several months to 2 years [34]. Anti-SARS-CoV-2 RBD responses in seropositive cats had similar declines in antibody titers only lasting around 4-5 months [35]. However, humans infected with the initial SARS-CoV mounted robust responses detectable 1-2 years post exposure [36-38]. The duration of anti-SARS-CoV-2 antibody responses is the subject ongoing research, but natural exposure is unlikely to induce long-term or lifelong immunity/seropositivity [39].

Major antigenic targets for SARS-CoV-2 infected individuals are the nucleocapsid, which is one of the most abundantly produced viral proteins [40], and spike protein, which is responsible for viral entry [41]. The spike has high immunogenicity and diverges from other coronaviruses [29, 41, 42]. Spike is composed of two subunits (S1/S2). The S1 subunit contains the receptor binding domain (RBD) responsible for binding to host ACE-2 and determining tropism/entry, while the S2 domain contains the fusogenic region of the spike [41, 42]. SARS coronaviruses share very low similarity to other coronaviruses within the spike protein [29], but antibodies against the S2 subunit can cross-react with common human coronaviruses [43-45]. Cross-reactivity of the S1 subunit occurs at very low rates. Within the S1 region, the RBD is highly immunogenic and unique to SARS-CoV-2 [29, 46]. Serum from humans infected with common human coronaviruses such as OC43, NL63, and 229E failed to recognize the RBD from SARS-CoV-2 [29, 43, 46]. Animals infected or immunized with other coronaviruses similarly fail to generate cross-reactive antibodies against SARS-CoV-2’s RBD [29]. For infected cats, SARS-CoV-2 seroconversion was not impacted by pre-existing immunity against feline coronavirus (FCoV), an alpha-coronavirus with limited similarity to SARS-CoV-2 [35]. Collectively, seropositivity against the RBD of SARS-CoV-2 is a specific marker of SARS-CoV-2 exposure and has led several groups to create highly specific indirect ELISAs against SARS-CoV-2’s RBD to screen for SARS-CoV-2 exposure [27, 29, 30]. A final consideration of antibodies targeting the RBD is they could be either neutralizing or non-neutralizing [30, 47-50]. This may explain why serum from humans and animals exposed to the original SARS-CoV were able to recognize the spike and RBD of SARS-CoV-2 while their cross-neutralization potential was variable [51, 52].

Despite limited similarity in the spike protein of SARS-CoV-2 vs common circulating coronaviruses, there are reports of pre-pandemic, pre-existing SARS-CoV-2 reactive serum in humans [45, 46, 51]. These cross-reactive antibodies represent a rare response to common human coronaviruses within conserved epitopes of SARS-CoV-2’s spike protein (usually in the S2 region) with reports of ∼0.6% prevalence of pre-existing anti-RBD responses [43, 45, 46]. Although there is increasing evidence for earlier timelines of SARS-CoV-2 spread among humans, pre-existing seropositivity among other species has not been reported [35, 53-55]. Indeed, even within central China, researchers failed to find evidence of SARS-CoV-2 exposure prior to the pandemic [35, 53, 55].

As SARS-CoV-2 spreads and encounter’s new species, there is a need for monitoring local populations for SARS-CoV-2 transmission and the potential establishment of local reservoirs. Currently, we have a limited understanding of coronavirus reservoirs, spread, and recombination among diverse species. The original SARS outbreak in 2003 was a harbinger of the potential risk of crossover coronaviruses. At that time, animal coronavirus surveillance was a high priority. Unfortunately, this investment was not sustained. Our aim was to address whether SARS-CoV-2 is being introduced into companion animals of North America by tracking seroconversion using an in-house indirect ELISA against the RBD of SARS-CoV-2. We chose to focus on companion animals (i.e., cats and dogs) as they represent a significant source of human-animal interactions with potential for contact and further spillover into wild animal populations. Surprisingly, we found evidence of anti-RBD seropositive animals pre-dating the pandemic by several months to years. Our study provides evidence for the existence and prevalence of SARS-CoV-2 serum reactivity prior to the current pandemic.

Materials and methods

Recombinant RBD production

Recombinant RBD production has been previously published [56]. Our lab deviated from the prior published method to utilize equipment readily available. Briefly, the plasmid containing the RBD of SARS-CoV-2 was produced under federal contract HHSN272201400008C and obtained through BEI Resources, NIAID, NIH. Vector pCAGGS contains the SARS-related coronavirus 2, Wuhan-Hu-1 spike glycoprotein RBD, NR-52309. To produce recombinant RBD, the pCAGGS-RBD plasmid was transfected into ∼5×107 adherent HEK-293/T17 cells (ATCC CRL-11268) in a T-175 using PEI (Polyethylenimine, linear 25,000 m.w.(Polysciences, Warrington, PA, USA). Plasmid was mixed at a 1:3 ratio with PEI (20ug of plasmid : 60ug PEI for a T-175 transfection) in 1 mL serum-free DMEM for 30 minutes at room temperature. Media was aspirated and the transfection mixture was added to 14mL fresh growth media and placed onto cells. Three to four hours post-transfection, media was changed and replaced with DMEM containing either 2% or 5% Fetal Bovine Serum (Hyclone FetalClone III, Cytiva Life Sciences, USA). Maintenance in a lower serum prevents overgrowth. However, we found higher protein yields when supplemented with 5% FBS (Supplemental Figure 4). Transfection efficiency was nearly 100% as assessed by GFP-positive transfected cells in a control flask.

Recombinant RBD purification

Supernatants from transfected HEK-293 T17 cells were collected into 50mL conical tubes and frozen at days 3 and 6 post-transfection. Pooled supernatants were thawed and incubated with Ni-NTA (Ni-NTA Agarose, Qiagen, Germany) resin with gentle rocking overnight. The resin was spun down at >3400x g’s in a swing-bucket Sorvall RT centrifuge for 10 minutes at 4°C. Ni-NTA resin was resuspended in 1mL wash buffer (20mM imidazole, 5mM NaH2PO4.H2O, 0.3M NaCl in H20), transferred to a 2mL microcentrifuge tube, gently rocked for 10 minutes at room temperature, spun, and resuspended in fresh buffer. Resin was washed between 3-7 times until OD230 was ≤ wash buffer. Once the supernatant OD dropped sufficiently, 1mL elution buffer (235mM Imidazole, 5mM NaH2PO4.H2O, 0.3M NaCl in H20) was added to elute the RBD from the nickel resin. Eluate was rocked for 10 minutes at room temp and then centrifuged. Two elution steps were performed with a third final elution using 0.5M imidazole. Supernatant at each stage was stored for RBD-binding analysis. Protein concentration was determined by standard curve analysis of a silver-stained (Pierce Silver Stain Kit, Thermo Scientific, USA) 12% SDS-PAGE gel using a standard curve of BSA (bovine serum albumin). Analysis was performed using Image Studio Lite ver. 5.3 (Li-Cor Biosciences, Lincoln, NE, USA). Purified RBD and elution steps are shown in Supplemental Fig 4.

Serum and Plasma samples

Previously collected pre-SARS-CoV-2 de-identified human serum samples were kindly donated by Dr. Jon Wall and Steve Foster (University of Tennessee Medical Center, Knoxville, Tennessee, USA). De-identified COVID-positive plasma samples were donated from: MEDIC Regional Blood Center (Knoxville, Tennessee, USA) and Dr. Mark Slifka (Oregon Health Sciences University, Portland, Oregon, USA). The following reagents were obtained through BEI Resources, NIAID, NIH: Human Plasma, Sample ID WU353-073, NR-53643; WU353-074, NR-53644; WU353-075, NR-53645; WU353-076, NR-53646; WU353-076, NR-53647, were contributed by Ali Ellebedy, Ph.D., Washington University School of Medicine, St. Louis, Missouri, USA. The following reagents were obtained through BEI Resources, NIAID, NIH: polyclonal anti-feline infectious peritonitis virus, 79-1146 (antiserum, guinea pig), NR-2518; polyclonal anti-canine coronavirus, UCD1 (antiserum, guinea pig), NR-2727; polyclonal anti-bovine coronavirus, Mebus (antiserum, guinea pig), NR-455; polyclonal anti-porcine respiratory coronavirus, ISU-1 (antiserum, guinea pig), NR-459; polyclonal anti-turkey coronavirus, Indiana (antiserum, guinea pig), NR-9465. Client-owned canine and feline serum samples were submitted to the University of Tennessee Veterinary Hospital for routine animal testing. Twenty cat samples were grouped into FCoV positive and negative groups based on feline infectious peritonitis (FIP) serology using an immunofluorescence assay (IFA) against FIP-2 (VMRD, Pullman, WA, USA). Normal cat serum was purchased from Jackson ImmunoResearch (West Grove, PA, USA).

Anti-RBD ELISA

Anti-RBD ELISA was based on the published protocol by Amanat et al. and Stadlbauer et al. [27, 56]. Purified RBD was diluted to 2ug/mL in PBS and 50uL was placed into each well of a 96 well plate (Immulon 4HBX, Thermo Fisher, USA) and allowed to incubate overnight at 4°C. Unbound RBD was removed and wells were washed 3x with PBS-T (PBS with 0.1% Tween-20). Rinsed wells were blocked with 5% milk in PBS for 2 hours at room temp. Block was removed and serum or plasma samples were added at 1:50 dilution for the initial screen in PBS with 1% milk and incubated at room temp for 1 hour. After 1 hour, wells were washed 3x with PBS-T and a secondary antibody for that species was added (i.e., HRP goat-anti-human IgG, Rockland Immunochemicals, Pottstown, PA, USA; HRP goat-anti-dog IgG, Bethyl Laboratories, Montgomery, TX, USA; HRP goat-anti-cat IgG, Invitrogen, Waltham, MA, USA; HRP goat-anti-guinea pig IgG, Life Technologies Corp, Carlsbad, CA, USA; HRP rabbit-anti-deer IgG, KPL, Gaithersburg, MD, USA; HRP sheep-anti-cow IgG, Bethyl Laboratories, Montgomery, TX, USA) at dilutions of 1:10,000 (anti-human, cat, dog, tiger) or 1:250 (anti-cow, deer, elk) in PBS with 1% milk. Optimal secondary antibody concentrations were determined by titration on either 5% milk (negative control) or 1:50 dilution of that species serum (positive control) (Supplemental Figure 2). Secondary antibodies were allowed to incubate for 1 hour at room temp before being washed 3x with PBS-T. ELISA was developed with 50uL TMB (1-Step Ultra TMB-ELISA, Thermo Fisher, Waltham, MA, USA) for 10 minutes. Reactions were stopped by the addition of 2M sulfuric acid and plates were read using a BioTek Synergy 2 or Synergy H1 plate reader set at 450nm (BioTek, Winooski, VT, USA). Receiver operator curve (ROC) analysis was performed to the determine the appropriate threshold to yield 100% specificity of ELISAs performed at a 1:50 dilution. For titrations of seropositive and seronegative samples, threshold values for each dilution were calculated as the average of negative samples plus 3 times the standard deviation. Titrated samples were initially diluted 1:100 and then serially diluted 1:3 (final dilution of 1:8100). Serum dilutions were made in PBS with 1% milk and added to RBD-coated and blocked wells. OD450 values for each species and titration were graphed in GraphPad Prism ver. 8 (GraphPad Software, San Diego, CA, USA).

Western and dot blots

For dot blots, 5-10uL of sample was applied directly onto nitrocellulose membranes and allowed to dry. Western blots were loaded with 30uL (∼3ug) of purified recombinant RBD, resolved in a 12% SDS-PAGE gel and transferred to a nitrocellulose membrane. Blots were blocked overnight at 4°C with 5% milk in PBS. Primary antibodies of HRP conjugated mouse anti-6His (Proteintech, Rosemont, IL, USA) at 1:5,000 or polyclonal serum samples at 1:20 were incubated on blots at room temperature for 2 hours and subsequently washed 2x with TBS-T (Tris Buffered Saline with 0.1% Tween-20). For polyclonal serum, species specific HRP anti-IgG antibodies (1:5,000 dilution) were incubated for an additional 2 hours and washed 2x as above. Chemiluminescent substrate (Pierce SuperSignal West Pico PLUS, Thermo Fisher, USA) was added and luminescence was detected using BioRad ChemiDoc (Bio-Rad, Hercules, CA, USA).

Neutralization assays

Serum samples were screened for neutralization using LEGENDplex SARS-CoV-2 neutralizing antibody assay (BioLegend, San Diego, CA, USA) following manufacturer recommendations. Briefly, serum was diluted 1:100 and incubated with biotinylated SARS-CoV-2 S1 subunit which contains the RBD and human ACE-2 (hACE-2) conjugated to fluorescent beads. Streptavidin-PE (phycoerythrin) was added to detect binding of SARS-CoV-2 S1 subunit to beads/hACE-2. Binding/PE levels were detected via a BD LSR-II equipped with 488 and 633nm lasers (Becton Dickinson, Franklin Lakes, NJ, USA). Data was analyzed using BioLegend LEGENDplex Data Analysis Software. Mean fluorescent intensity (MFI) was normalized and graphed in GraphPad prism v9 (GraphPad Software, San Diego, CA, USA).

Fecal coronavirus screen and sequence alignments

De-identified fecal samples from twenty-one healthy East Tennessee cats were collected and immediately stored at -80°C. Samples were resuspended in PBS to yield a 10% solution and centrifuged to clarify. Fecal RNA was extracted using a Qiagen viral RNA extraction kit (Qiagen, Hilden, Germany) and RNA was reverse transcribed using Verso cDNA kit with random hexamers and RT enhancer (Thermo Fisher, Waltham, MA, USA). PCR amplification of conserved coronavirus regions using previously reported primer pairs was used to screen the cDNA [57]. PCR amplicons were visualized on a 1% agarose gel and positive PCR samples were Sanger dideoxy sequenced. Sequences were viewed using 4Peaks software (Nucleobytes, Amsterdam, Netherlands). Sequences from fecal samples were Clustal W aligned to common coronaviruses, trimmed and a phylogenetic tree generated using Maximum-Likelihood method for each positive loci using MEGA X [58, 59]. For phylogenetic trees using multiple loci, aligned and trimmed sequences for each loci were concatenated together prior to Maximum-Likelihood tree construction. Phylogenetic trees were tested by bootstrap testing with 1000 iterations. Common coronavirus sequences for ORF1ab (RdRp and helicase loci) and spike were obtained from the following: porcine coronavirus HKU15 (NC039208), SARS-CoV-2 (MN988668), SARS-CoV (NC004718), porcine respiratory coronavirus/PRCoV (KY406735), human coronavirus OC43 (NC006213), MERS-CoV (NC038294), feline coronavirus/FcoV (NC002306), canine respiratory coronavirus/CRCoV (KX432213), canine coronavirus/CCoV (JQ404410), bovine coronavirus/BCoV (NC003045), avian coronavirus (NC048214), human coronavirus 229E (NC002645), transmissible gastroenteritis virus/TGEV (NC038861), murine hepatitis virus/MHV (NC048217), human coronavirus NL63 (NC005831), feline coronavirus strain UU8 (FJ938055), feline coronavirus strain UU19 (HQ392470), feline coronavirus strain Black (EU186072), feline coronavirus strain RM (FJ938051), feline coronavirus strain Felix (MG893511). All generated sequences were deposited in GenBank under accession numbers: MZ220722 through MZ220762 (sample ID, positive loci, animal location, and accession numbers are shown in Supplemental Table 1).

Statistics

All graphs and statistical analysis were performed in GraphPad Prism ver. 9 (GraphPad Software, San Diego, CA, USA). ELISA OD450 results were normalized to an inter-plate replicate run with all assays. Student’s one-tailed t-tests with Welch’s correction and one-way ANOVA with multiple comparisons tests were performed on ELISA results and documented in the respective figure legends. Descriptive statistics were provided for each ELISA group (mean, median, and quartiles). Receiver operator curve (ROC) analysis was performed to determine appropriate threshold values for human, cat, and deer serum samples. Area under the curve was calculated for each titrated ELISA sample and graphed. Neutralization data was normalized with negative control group (normal cat serum) representing 100% MFI.

Data will be made publicly available upon publication and upon request for peer review.

Results

We developed an in-house assay to serologically screen companion animals based on a protocol developed at Mt. Sinai [27, 56]. To examine cross-reactivity of our in-house anti-SARS-CoV-2 RBD indirect ELISA, we used polyclonal guinea pig serum raised against different animal coronaviruses (Fig 1A). Consistent with previous reports, no cross-reactive antibodies for any of the common coronaviruses were found [18, 29, 35, 53]. Only antibodies from SARS-CoV or SARS-CoV-2 infected individuals reacted (Fig 1A, 1B). Human serum collected from individuals prior to the SARS-CoV-2 pandemic or plasma from recovered SARS-CoV-2 donors were used to validate our ELISA screen (Fig 1B). ROC analysis determined the positive cutoff threshold, using a value that gave highest specificity and sensitivity with pre-pandemic human serum and serum from confirmed SARS-CoV-2 infected individuals. ROC analysis was in agreement with the commonly used threshold determination method of three standard deviations above the mean negative value. Our assay based on RBD screening showed high sensitivity (96.96%) and specificity (95.45%) with 66 SARS-CoV-2 samples and 22 pre-SARS-CoV-2 samples (Fig 1B). While Stadlbauer et al. performed two diagnostic ELISAs, one with RBD and the other with full-length spike, our results using only the RBD-based screen are in good agreement with their published data. Others have also demonstrated the accuracy of an RBD-only based ELISA [30, 35]. A western blot using an anti-6His antibody in Fig 1C shows the expected size of purified RBD with a single band ∼32kDa. This shows that our isolated RBD is the correct size and runs as a monomer.

Figure 1:
Figure 1: Anti-SARS-CoV-2 ELISA Sensitivity and Specificity.

(A) Cross reactivity of anti-CoV antibodies against SARS-CoV-2 RBD. Polyclonal sera from guinea pigs immunized with common animal coronaviruses (turkey coronavirus, TCoV; porcine respiratory coronavirus, PRCoV; canine coronavirus, CCoV; feline coronavirus, FCoV; bovine coronavirus, BCoV) was used in a SARS-CoV-2 RBD indirect ELISA. Positive samples consisted of polyclonal serum from a SARS-CoV-2 infected patient and a monoclonal antibody to SARS-CoV (CR3022). The negative control group was comprised of pre-pandemic human serum. Secondary antibodies were either anti-human IgG (1:10,000) (Rockland Immunochemicals, USA) or anti-guinea pig IgG (1:10,000) (Life Technologies Corp, USA). Bars represent mean and standard deviation (n>3 for all samples). (B) ELISA validation using 66 human Covid-positive plasma and 22 negative serum samples. Human antibodies against the SARS-CoV-2 RBD were detected with an indirect RBD-specific ELISA. Secondary antibody was the anti-human IgG (1:10,000) (Rockland Immunochemicals, USA). ROC analysis determined the positive OD450 cutoff value (dashed line). Positive plasma samples were donated COVID recovered patients and pre-pandemic serum samples were the negative controls. Based on the experimentally determined cutoff value, 64 of the 66 positive samples were anti-RBD positive, giving a sensitivity value of 96.96%. All but one of the negative samples were below the cutoff value for a specificity of 95.45%. Adjacent tables list first and third quartiles along with mean and median OD450 values of COVID-positive and negative human samples. Bars represent mean and standard deviation (n>3). (C) Anti-6His western blot on HEK-293T17 purified RBD from 5% serum conditions. Samples were run on a 12% denaturing SDS-PAGE gel. Protein was transferred to nitrocellulose and probed with anti-6His antibody at 1:10,000 (Proteintech, USA). White light and chemiluminescent images were overlaid and from left to right, ladder (lane 1) and purified RBD (lane 2). For B and C, representative data shown.

To establish a baseline for future SARS-CoV-2 screening of companion animals, 128 pre-pandemic feline serum samples collected prior to December 2019 were retrospectively screened using our in-house ELISA. Nineteen samples were of a known FCoV serological status, with the remaining 109 of unknown FCoV status. Following the same protocol used for screening human serum samples (Fig. 1), feline samples were tested for antibodies against SARS-CoV-2’s RBD (Fig 2A). There were two batches that were tested. Serum samples from feral cats in East Tennessee were collected from 2007 to 2012 (2007-2012) (n=36) and convenience samples from client owned cats undergoing routine blood work (listed as Pre-pandemic) (n=92) (Fig 2A). As expected, SARS-CoV-2 experimentally infected cats [14] tested positive with high relative OD450, and normal cat serum (i.e., negative control) had very low relative OD450 (Fig 2A). Surprisingly 52% (67/128) of the cat samples tested positive for antibodies against SARS-CoV-2 RBD despite pre-dating the pandemic. As both positive and negative anti-RBD serum samples were found in the FCoV positive group (Fig 2A), prior FCoV pre-existing immunity does not generate RBD cross-reactivity. This is consistent with the lack of high anti-FCoV cross-reactivity in guinea pigs in Fig 1A, as well as several other reports showing a lack of similarity and cross reactivity between alpha coronaviruses and SARS-CoVs [18, 29, 35, 53]. Indeed, two other research groups found that pre-existing immunity to FCoV had no impact on seropositivity of feline samples [35, 55]. To ensure that the positive ELISA result was specific to the RBD and not to a co-purified protein, a western blot was carried out using serum from a positive sample (Fig 2B). Positive cat serum bound a ∼32 kDa protein, the size of the RBD protein (Fig 1C). Notably, normal cat serum did not react with any other protein despite the presence of co-purified proteins. To further show the specificity of the anti-RBD response, we titrated seropositive and seronegative samples. Starting with serum from cats experimentally infected with SARS-CoV-2 (Fig 2A) and normal cat serum, saw a normalized OD450 >3 standard deviations above the negative control (i.e., normal cat serum) at all dilutions. This gives a titer >8100 (Fig 2C). 17 seropositive and 8 seronegative pre-2020 cat samples were titrated and assayed in our ELISA (Fig 2D). Titers ranged from 900 to 8100, with a median titer of 2700 demonstrating both a high anti-SARS RBD prevalence and titer. Titrations of these earlier seropositive and seronegative feral cat samples have a similarly high titer (Fig 2E) (median titer 8100) which is on par with the pre-pandemic samples. AUC for all groups is shown to the right side of their respective titration. AUC analysis of the titrated samples showed a significant difference between all positive and negative samples.

Figure 2:
Figure 2: Pre-Pandemic Feline Antibodies Cross-React with SARS-CoV-2 RBD.

(A) ELISA results of cat serum RBD reactivity. 93 pre-pandemic feline serum samples were tested for reactivity in our anti-RBD ELISA with anti-felid IgG secondary (1:10,000) (Invitrogen, USA). Cutoff values were determined by receiver operator curve (ROC) analysis. OD450 for samples in each group were plotted with the dotted line representing the positive threshold. Two sets of pre-pandemic cat samples were collected. Pre-pandemic cat convenience samples (n=73) were collected in local clinics and sent to the University of Tennessee for diagnostic testing or during feral cat studies (2007-2012) (n=36). Pre-pandemic convenience samples were subdivided into feline coronavirus positive (FCoV+) and negative (FCoV-) subgroups. Normal cat serum (Jackson ImmunoResearch Laboratories, USA) serves as the negative control and SARS-CoV-2+ serum from two cats experimentally inoculated with SARS-CoV-2 are positive controls. Side table lists first and third quartiles and mean and median OD450 values for all samples. Bars represent mean +/-standard deviation (n>3 for all samples). (B) Western blot of purified RBD using serum from a single positive cat sample. Purified RBD was run under denaturing conditions and blotted onto nitrocellulose. The RBD blot was first probed with cat serum from an ELISA positive sample (1:20 dilution) followed by anti-felid IgG (1:10,000 dilution) (Invitrogen, USA). White light and chemiluminescent images were overlaid. Lane 1 is the molecular weight ladder and lane 2 is purified RBD. (C, D, E) Titration of seropositive and seronegative serums assessed via RBD ELISA. OD450 values were plotted against the reciprocal dilution. Samples were considered positive if they were 3 standard deviations above the negative average for each dilution. Anti-RBD titer was designated as the last dilution above the negative cutoff. Positive controls were human COVID-positive serum and negative controls were normal human and cat serum (Jackson ImmunoResearch Laboratories, USA). Statistics for the positive sample titrations are included in the table along with AUC analysis. (C) Serum from two SARS-CoV-2 infected cats (♦) and normal cat serum (Δ) were titrated in an anti-RBD ELISA. (D) Titration of 17 seropositive and 10 seronegative, pre-pandemic cat samples. (E) Titration of four seropositive and seronegative cat samples collected from 2007-12. For A and B, representative data shown. For A, Tukey’s one-way ANOVA with multiple comparisons was performed. For C, D, E AUC analysis and Student’s one-tailed t-test with Welch’s correction was performed. p< 0.05 = *, p< 0.01 = **, p< 0.001 = ***.

Following the surprising presence and prevalence of anti-RBD responses in pre-pandemic cats, we explored the epidemiological characteristics of our samples. Pre-pandemic convenience samples were submitted to the University of Tennessee for diagnostic testing of feline herpesvirus, feline calicivirus, and FCoV. Age, sex, and location of seropositive and seronegative samples are shown in Table 1. Both seropositive and seronegative samples had a mean age of >3 years with no difference between the groups and contained similar ratios of male: female animals (Table 1). Seropositive samples were found in disparate geographic locations from opposite coasts of the United States (i.e., New York to California (Table 1)). This observation indicates that seropositivity or exposure is not confined to a single geographic region (e.g., East Tennessee). Based on our limited sampling, we were unable to identify any unique characteristic or identifier for seropositive vs seronegative samples.

View this table:
Table 1: Characteristics of Feline Samples

Cats were grouped based on the seronegative/positive status from the ELISA from Fig 2A. Student’s t-test was used to determine significance (ns = not significant).

With our discovery of pre-existing antibodies against SARS-CoV-2’s RBD, it was pertinent to examine samples from dogs, another companion animal with high contact with humans. Serum samples from dogs (n=36) were collected and retrospectively screened as part of a tick study during a 7 month period beginning in Jan 2020 and extending into July 2020. We consider these post-pandemic samples because the sample collection timeframe straddles the arrival of SARS-CoV-2 in East Tennessee (∼March 2020). The initial ELISA screen identified 97% seropositivity in the dog samples (Fig 3A) with only 1 sample falling below the cutoff established on human serum. Surprisingly, serum from purpose-bred research animals housed at the University of Tennessee also showed high levels of reactivity (Fig 3A). This raised suspicion about the specificity of the response. To address this, western blot analysis with canine serum (Fig 3B) identified a protein other than the RBD (see the ∼32 kDa protein in Fig 1C and 2B). The canine serum recognized a ∼60 kDa protein which is likely a co-purified protein present after RBD purification and can be faintly seen in silver-stained gel in Supplemental Fig 1A. This co-purified protein was not detected in the blots performed for Fig. 1C and 2B using anti-6His monoclonal antibody and cat serum, respectively. Although there is a possibility that canine serum recognizes an oligomer of RBD, based on Fig 1C the anti-6His antibody does not detect any >32kDa band [60].

Figure 3:
Figure 3: Dog Serum Reacts to a Co-Purified Protein.

(A) Anti-SARS-CoV-2 RBD ELISA with dog serum. Serum from thirty-six client-owned and two purpose-bred research dogs were tested in an anti-RBD ELISA with anti-canine IgG secondary (1:10,000) (Bethyl Laboratories, USA). Table to the right lists the first and third quartiles, median, and mean OD450 values for all samples. Bars represent mean +/-standard deviation (n>3) (B) Western blot of purified RBD using serum from a positive dog sample. Purified RBD was probed with dog serum from an ELISA positive sample (1:20 dilution) followed by anti-canine IgG (1:10,000 dilution) (Bethyl Laboratories, USA). White light and chemiluminescent images were overlaid. Lane 1 (from left to right) ladder and lane 2: purified RBD. For all figures, representative data shown.

Following our observation of high levels of anti-SARS-CoV-2 RBD antibodies in North American cats, we began examining other regional animals. Serum from Tennessee resident, pre-pandemic cows (n=33) and tigers (n=9), post-pandemic East Tennessee elk (n=12), and post-pandemic South Carolina deer (n=22) were tested for anti-SARS-CoV-2 RBD antibodies (Fig 4A). Of the four species tested, only the deer from South Carolina showed any seropositive samples (2/22). Serum titrations show the two seropositive samples have a high titer >8100 (Fig 4B), and AUC of the titrations show a significant difference between seropositive and negative deer samples (Fig 4C). Unfortunately, due to limited sample volume, we were unable to attempt western blots to demonstrate whether the deer antibodies were specific RBD protein. The deer are post-pandemic and could represent recent transmission of SARS-CoV-2 into the deer population. Although these animals probably have had limited contact with humans, white-tailed deer are susceptible to and capable of transmitting SARS-CoV-2 [61]. Another possibility is that this species was exposed to the same etiological agent as our pre-pandemic seropositive cats.

Figure 4:
Figure 4: Serological Testing of Other Regional Animals.

(A). Anti-SARS-CoV-2 RBD ELISA with bovine, elk, tiger, and deer serum. Thirty-three pre-pandemic East Tennessee cows, twelve post-pandemic East Tennessee elk, nine pre-pandemic East Tennessee tigers, and twenty-two post-pandemic South Carolina deer serum samples were tested for anti-RBD antibodies. Species-specific secondary antibodies were used at the following dilutions: anti-bovine 1:250 (Bethyl Laboratories, USA), anti-elk/deer 1:250 (KPL, USA), anti-tiger/cat 1:10,000 (Invitrogen, USA), and anti-deer 1:250 (KPL, USA). Bars represent mean +/-standard deviation (n>3 for all samples). (B) Titration of two seropositive (♦) and four seronegative (Δ) deer samples. OD450 values are plotted against the reciprocal dilution of each sample. Samples were considered positive if they were 3 standard deviations above the negative average for each dilution. Positive and negative controls were human COVID-positive and negative samples, respectively. Statistics for the positive sample titrations are included in the table. The AUC analysis for titrations of deer ELISA positive and negative samples is shown to the right. For all figures, representative data shown. For AUC analysis Student’s one-tailed t-test with Welch’s correction was performed. p< 0.05 = *, p< 0.01 = **, p< 0.001 = ***.

To address whether these samples can neutralize SARS-CoV-2 infections, we measured the ability of cat serum to block the interaction of the spike protein with the human ACE-2 (hACE-2) receptor using a commercially available flow cytometry-based bead assay. In this assay, neutralization is characterized as the decrease in fluorescence when antibodies block the fluorescently labeled SARS-CoV-2 S1 subunit from binding to hACE-2 conjugated beads (Fig 5A). Because this assay is not species specific or immunoglobulin type dependent, it is applicable for assessing both human and feline serum. The internal antibody control shows a decrease in fluorescence corresponding to levels of neutralizing monoclonal antibody against SARS-CoV-2 (Supplemental Fig 4). Serum from experimentally infected cats showed potent neutralization at 1:100 dilution. However, only one ELISA-positive, pre-pandemic cat sample showed neutralization (Fig 5B). A single serum sample from mice immunized with PRCoV also showed slight neutralization. Both samples barely cleared the ROC threshold value. Notably, we were unable to detect high levels of neutralization/neutralizing antibodies even in several human convalescent serum samples (Supplemental Fig 4).

Figure 5:
Figure 5: Neutralization Assays.

(A) Schematic of the neutralization assay. Neutralization is measured as the decrease in binding of phycoerythrin (PE)-labeled SARS-CoV-2 S1 subunit to human ACE-2 conjugated beads. Addition of neutralizing antibodies results in a decreased mean fluorescent intensity (MFI) as measured by flow cytometry. (B) Neutralization of SARS-CoV-2 S1 subunit interaction with hACE2. Serum from several ELISA positive and negative cats (ELISA+ and ELISA-, respectively) and mice immunized with other common coronaviruses (BCoV=bovine coronavirus, TCoV= Turkey coronavirus, PRCoV=porcine respiratory coronavirus, FCoV=feline coronavirus, CCoV=canine coronavirus). SARS-CoV-2 infected cats and normal cat serum served as positive and negative controls, respectively. Data was normalized to normal cat serum representing 100% binding of SARS-CoV-2 S1 subunit to hACE2 beads. ROC analysis was used to generate a positive reduction threshold (dotted line). Each point is an average of 2 replicates. A Tukey’s one-way ANOVA with multiple comparisons was used to analyze experimental groups. ns=not significant.

Because cross-reactivity to the SARS-CoV-2 RBD independent of SARS-CoV-2 infection has not been previously reported in felines, we explored the etiological agent potentially responsible for seropositivity [35, 55]. Fecal samples were collected from healthy East Tennessee cats and screened for coronaviruses using pan-coronavirus primers amplifying conserved regions of the RdRp (RNA-dependent RNA polymerase), helicase (Hel), and spike (S) genes [57]. Fifteen out of thirty samples (50%) tested positive for at least one loci, with most yielding positive results for multiple loci (Supplemental Table 1). Not surprisingly, sequences cluster within the alpha-coronavirus group (Supplemental Figure 3) and with high similarity to previously identified FCoV. When all five loci were aligned and concatenated together, the Maximum-Likelihood phylogenetic tree places the concatenated coronavirus sequences within the alpha-coronavirus lineage, closely related to the FCoV lineage (Fig 6A). We were unable to amplify or identify any sequences which resemble SARS-like coronaviruses or beta-coronaviruses.

Figure 6:
Figure 6: Pan Coronavirus Screen of East Tennessee Felines.

Fecal samples from healthy cats were collected and screened for conserved coronavirus sequences. Phylogenetic tree consisting of common human and animal coronaviruses: CRCoV (canine respiratory coronavirus), BCoV (bovine coronavirus), OC43 (human beta-coronavirus), MHV (murine hepatitis virus), MERS-CoV (Middle East respiratory coronavirus), SARS-CoV-2 (severe acute respiratory coronavirus-2), SARS-CoV (severe acute respiratory coronavirus), AvianCoV (duck coronavirus), NL63 (human alpha-coronavirus), 229E (human alpha-coronavirus), TGEV (transmissible gastroenteritis virus), PRCoV (porcine respiratory coronavirus), FCoV (feline coronavirus strains UU19, Felix, RM, Black, UU8), CCov (canine coronavirus), HKU15 (porcine delta-coronavirus), as well as a locally identified coronavirus (CP-20-26). Sequences from five coronavirus loci were independently aligned, trimmed, and concatenated together. Concatenated sequences were aligned and phylogenetic trees generated with the Maximum-Likelihood method with bootstrap analysis in MEGA X. Bootstrap values for each branch are shown with lengths to scale. Coronavirus lineages are annotated on the tree.

Discussion

Our indirect ELISA screen has provided possible evidence for a SARS-like virus infection of North American cats and deer. For the purposes of this study, we have defined a “SARS-like” virus based on its ability to generate cross-reactive antibodies against the RBD of SARS-CoV-2. The common human and animal coronaviruses (both alpha and beta coronavirus families) do not generate cross-reactive antibodies against this protein, making it as a SARS-specific response [27, 29, 30, 35, 43, 46]. However, SARS coronaviruses likely originated from bat coronaviruses and maintained sequence similarity with them, even in the somewhat unique RBD region [29]. This high degree of similarity could generate of cross-reactive antibodies against SARS-CoV-2’s RBD. Conceivably, our definition of SARS-like coronavirus could also encompass bat coronaviruses due to amino acid similarity and potential cross reactivity in the RBD region.

We employed serological screening as a method to detect SARS-CoV-2 exposure in animal populations. Tracking active viral spread in wild and domesticated animals in real-time via sequencing and RT-qPCR is expensive and low throughput. In addition, the unknown transient nature of viral shedding from different secretions/locations makes this type of surveillance prohibitively expensive with no guarantee of identifying a virus. Serological detection of antibodies against SARS-CoV-2 is comparatively high-throughput and inexpensive while still maintaining sensitivity. A downside of this methodology is the lack of an up-to-date picture of cross-species transmission, as serology trails initial infections by several days to weeks [22, 30]. On the other hand, due to the lowered cost of serological testing there is a compensatory increase in testing capability allowing a broader swath of animals and regions to be sampled with more frequent re-sampling to track spillover into new species. Our adapted protocol yields recombinant SARS-CoV-2 RBD protein allowing production of a low-cost indirect anti-RBD ELISA. The recombinant RBD was sufficient for serological screening via ELISA and is amenable to most labs with prior tissue culture capabilities and does not require large initial investments in cell lines, culture media, or specialized incubators. We validated our method demonstrating low cross-reactivity with other common animal coronaviruses (Fig 1A) and >95% sensitivity and specificity on human serum samples (Fig 1B).

The current study presents evidence for the presence and circulation of a “SARS-like” coronavirus among animals that predates the current SARS-CoV-2 pandemic. This is in stark contrast to SARS-CoV-2 serosurveys on pre- and post-pandemic feline samples from Central China. They found no evidence of exposure before the outbreak, but also positivity levels post-pandemic were significantly lower than shown here (∼12% Central China vs >50% USA) (Fig 2A) [35, 55]. For the seropositive samples identified in our study, mean titers for positive cat samples were relatively high at ∼2700 (Fig 2E, G), which based on reported rapid declines in anti-RBD responses for SARS-CoV and FCoV points to infections with a SARS-like virus within the past few years. Further, based on FCoV studies, animals with high titers typically correlate with active viral shedding and spread within a household, which highlights a potential overlap between seropositivity and viral shedding [34]. OD450 and titers of pre-pandemic seropositive cat samples, while high, were lower than SARS-CoV-2 experimentally inoculated cats (6 weeks post infection) (Fig 2A, C, E, G). This likely represents a natural decline in titer over time for the environmental samples but could also represent a lower cross-reactive antibody from another coronavirus. To-date, cross-reactivity against the RBD of SARS-CoV-2 has only been reported for SARS and SARS-like coronaviruses [29, 43]. This leads us to the idea of prior exposure to SARS-like coronaviruses for North American cats. Based on the high seroprevalence in cats, we would consider this unknown coronavirus endemic for wild and domestic felids. Seropositive animals were geographically located on opposing coasts of North America (Table 1) which casts doubt on this infection being local. Instead, it points to a pervasive cross-reacting infection dating back several years prior to the pandemic. How it has spread into the local feline population at such high levels is unknown. At least within Tennessee there are numerous cave systems with several native species of bats potentially leading to an inter-species transmission, but whether there was direct transfer from bat to cat or an intermediary needs to be ascertained. Additionally, there is currently no evidence of either a circulating SARS-like or bat betacoronavirus in North America [62-65]. Along with potential interactions with native bats, North American deer mice were recently shown to be susceptible to human SARS-CoV-2 and capable of mouse-to-mouse transmission representing another possible point of introduction into the feline population [66].

Unfortunately, dog serum was shown to bind to a co-purified protein (Fig 3B), leaving us unable to utilize our assay for examining cross-species transmission of SARS-like coronaviruses to canines. We can show that recombinant RBDs produced and purified by groups at both Mt. Sinai and Emory contain co-purified proteins at approximately the same size as shown in Fig 1A [27, 30]. As such, screens for SARS-CoV-2 exposure in canines would likely require producing and purifying the RBD using a different strategy that eliminates contamination with other proteins. Recently both SARS-CoV-2’s RBD and soluble full-length spike have been produced and purified using plant culture methods [67]. This alternative method may prove useful for animal SARS-CoV-2 screening by reducing or eliminating false positives due to co-purified proteins.

After the discovery of pre-pandemic seropositive cats, we examined other commercial (cow) and convenience samples from local wild species (deer, elk, tiger) (Fig 4A). Two out of twelve (33%) white tailed deer from South Carolina were positive for antibodies against the RBD (Fig 4B). Unlike our cat samples, the two seropositive deer could represent transmission of SARS-CoV-2 into the local deer population because these samples were collected post pandemic. Interestingly, a recent report showed that 33% of white-tailed deer from 4 states (Illinois, Michigan, New York, and Pennsylvania) were positive for SARS-CoV-2 antibodies[68]. Seropositive animals were only observed from 2019 onward, with pre-pandemic deer testing negative on their SARS-CoV-2 neutralization assay. This information supports our finding in South Carolina deer. Although it is possible that these deer had contact with infected humans with SARS-CoV-2, this seems unlikely. What seems more likely is that there is a circulating virus, likely a beta coronavirus, that has an RBD like protein in it. It is quite possible that this is the same etiological agent generating anti-RBD responses in North American cats. However, SARS-CoV-2 sequences were recently isolated from the retropharyngeal lymph nodes of wild and captive deer [69]. Regardless, further work is needed to determine the prevalence, spread, and identity of a coronavirus-like infection in North American deer.

Neutralization of SARS-CoV-2 S1 subunit was only detectable in the SARS-CoV-2 experimentally inoculated cat samples (Fig 5B). There was no significant difference in MFI/neutralization between the anti-RBD seropositive and seronegative feline samples (Fig 5B). We would expect animals with high RBD recognition and titers to correlate with higher neutralization. However, that is not what we found. Several groups have looked at RBD binding antibodies and found that not all anti-RBD responses generate neutralizing antibodies [47-50, 70]. Indeed, even in convalescent serum, high levels of RBD recognition does not guarantee high neutralizing titers (Supplemental Fig 4) [47]. Based on ELISA and neutralization results (Fig 2A, Fig 5B), we can conclude that these animals contain antibodies that recognize SARS-CoV-2’s RBD, but likely bind to non-neutralizing epitopes of the RBD domain.

Because 50% of cats surveyed were seropositive, we reasoned that isolation of the suspected coronavirus might be possible. Based on the relationship between high titer and shedding of viral RNA in FCoV infected cats and the fecal-oral transmission of animal coronaviruses, PCR amplification with universal coronavirus primers of fecal sample was used to identify the causative agent for anti-RBD seropositivity. This allowed for non-invasive testing and isolation of coronavirus RNA from infected cats. In line with previous studies on other wild animals, we were unable to identify any non-alphacoronaviruses circulating in felines [62-65]. The coronavirus sequences had similarity to and likely represent normal circulating FCoV (Fig 6). Due to the opportunistic nature of our sampling, we were unable to obtain any paired blood and fecal samples from the same animal. Because of this sampling, we are unable to conclude whether the cats with these FCoVs cross-react with SARS-CoV-2’s RBD. Based on our ELISA results in Fig 1A and 2A, we would suspect not. Furthermore, because we do not know when these cats were exposed, these cats could have been infected potentially years prior to our fecal sampling and would not shed a novel coronavirus if they had cleared it. Following the identification of coronavirus positive fecal samples, we attempted to amplify and sequence the entire RBD region from positive samples to look for similarity to SARS-CoV-2 or SARS-like viruses. Unfortunately, we were unsuccessful in amplifying and determining the sequence in this variable region of the spike protein.

Conclusion

Our initial goal was to develop an ELISA assay for tracking the reverse zoonosis of SARS-CoV-2. However, when establishing our baseline on pre-pandemic cat samples we discovered seropositive serum for a SARS-specific antigen (i.e., RBD). Due to the seropositivity observed, we postulate that there likely exists a coronavirus or another virus with significant similarity to SARS-CoV-2’s RBD that is circulating within both feral and domestic cats of North America and has been for at least several years. Although we cannot disregard the possibility of a cross-reaction between a circulating animal coronavirus, our data and other studies discount this possibility. The high rate of SARS-CoV-2 RBD seropositivity within a common companion animal further highlights our need for a better understanding of the prevalence and crossover potential of wild coronaviruses. Further investigations should address shedding of viral RNA from the seropositive species (i.e., cats and deer) identified here to isolate, sequence, and identify this potential “SARS-like” coronavirus.

Acknowledgments

We would like to thank the following for their generous contributions making this work possible: MEDIC Regional Blood Center

Mark Slifka – Oregon Health Sciences University

Jon Wall and Steve Foster – University of Tennessee Medical Center Knoxville

Krammer Lab – Icahn School of Medicine at Mount Sinai

Wrammert Lab – Emory University

Angela Bosco-Lauth – Colorado State University

Jennifer Weisent, Rebekah DeBolt, Sarah Englebert, Jessica Thompson – University of Tennessee College of Veterinary Medicine Shelter Medicine Service

References

  1. 1.↵
    Poon LLM, Peiris M. Emergence of a novel human coronavirus threatening human health. Nat Med. 2020;26(3):317–9. Epub 2020/02/29. doi: 10.1038/s41591-020-0796-5. PubMed PMID: 32108160; PubMed Central PMCID: PMCPMC7095779.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. Epub 2020/02/29. doi: 10.1056/NEJMoa2002032. PubMed PMID: 32109013; PubMed Central PMCID: PMCPMC7092819.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Latinne A, Hu B, Olival KJ, Zhu G, Zhang L, Li H, et al. Origin and cross-species transmission of bat coronaviruses in China. Nat Commun. 2020;11(1):4235. Epub 2020/08/28. doi: 10.1038/s41467-020-17687-3. PubMed PMID: 32843626; PubMed Central PMCID: PMCPMC7447761.
    OpenUrlCrossRefPubMed
  4. 4.
    Li X, Giorgi EE, Marichannegowda MH, Foley B, Xiao C, Kong XP, et al. Emergence of SARS-CoV-2 through recombination and strong purifying selection. Sci Adv. 2020;6(27). Epub 2020/09/17. doi: 10.1126/sciadv.abb9153. PubMed PMID: 32937441.
    OpenUrlFREE Full Text
  5. 5.↵
    Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–2. Epub 2020/04/15. doi: 10.1038/s41591-020-0820-9. PubMed PMID: 32284615; PubMed Central PMCID: PMCPMC7095063.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Sun J, Xiao J, Sun R, Tang X, Liang C, Lin H, et al. Prolonged Persistence of SARS-CoV-2 RNA in Body Fluids. Emerg Infect Dis. 2020;26(8):1834–8. Epub 2020/05/10. doi: 10.3201/eid2608.201097. PubMed PMID: 32383638; PubMed Central PMCID: PMCPMC7392422.
    OpenUrlCrossRefPubMed
  7. 7.↵
    Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med. 2021;174(1):69–79. Epub 2020/09/18. doi: 10.7326/M20-5008. PubMed PMID: 32941052; PubMed Central PMCID: PMCPMC7505025.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020;323(18):1843–4. Epub 2020/03/12. doi: 10.1001/jama.2020.3786. PubMed PMID: 32159775; PubMed Central PMCID: PMCPMC7066521.
    OpenUrlCrossRefPubMed
  9. 9.
    Kim JM, Kim HM, Lee EJ, Jo HJ, Yoon Y, Lee NJ, et al. Detection and Isolation of SARS-CoV-2 in Serum, Urine, and Stool Specimens of COVID-19 Patients from the Republic of Korea. Osong Public Health Res Perspect. 2020;11(3):112–7. Epub 2020/06/13. doi: 10.24171/j.phrp.2020.11.3.02. PubMed PMID: 32528816; PubMed Central PMCID: PMCPMC7282421.
    OpenUrlCrossRefPubMed
  10. 10.
    Kang M, Wei J, Yuan J, Guo J, Zhang Y, Hang J, et al. Probable Evidence of Fecal Aerosol Transmission of SARS-CoV-2 in a High-Rise Building. Ann Intern Med. 2020;173(12):974–80. Epub 2020/09/02. doi: 10.7326/M20-0928. PubMed PMID: 32870707; PubMed Central PMCID: PMCPMC7464151.
    OpenUrlCrossRefPubMed
  11. 11.
    Xiao F, Sun J, Xu Y, Li F, Huang X, Li H, et al. Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. Emerg Infect Dis. 2020;26(8):1920–2. Epub 2020/05/19. doi: 10.3201/eid2608.200681. PubMed PMID: 32421494; PubMed Central PMCID: PMCPMC7392466.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Yu IT, Li Y, Wong TW, Tam W, Chan AT, Lee JH, et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med. 2004;350(17):1731–9. Epub 2004/04/23. doi: 10.1056/NEJMoa032867. PubMed PMID: 15102999.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    Roltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Najeeb J, et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020;5(54). Epub 2020/12/09. doi: 10.1126/sciimmunol.abe0240. PubMed PMID: 33288645.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    Bosco-Lauth AM, Hartwig AE, Porter SM, Gordy PW, Nehring M, Byas AD, et al. Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats. Proc Natl Acad Sci U S A. 2020;117(42):26382–8. Epub 2020/10/01. doi: 10.1073/pnas.2013102117. PubMed PMID: 32994343; PubMed Central PMCID: PMCPMC7585007.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020;368(6494):1016–20. Epub 2020/04/10. doi: 10.1126/science.abb7015. PubMed PMID: 32269068; PubMed Central PMCID: PMCPMC7164390.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    Wu L, Chen Q, Liu K, Wang J, Han P, Zhang Y, et al. Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. Cell Discov. 2020;6:68. Epub 2020/10/07. doi: 10.1038/s41421-020-00210-9. PubMed PMID: 33020722; PubMed Central PMCID: PMCPMC7526519.
    OpenUrlCrossRefPubMed
  17. 17.↵
    Segales J, Puig M, Rodon J, Avila-Nieto C, Carrillo J, Cantero G, et al. Detection of SARS-CoV-2 in a cat owned by a COVID-19-affected patient in Spain. Proc Natl Acad Sci U S A. 2020;117(40):24790–3. Epub 2020/09/20. doi: 10.1073/pnas.2010817117. PubMed PMID: 32948692; PubMed Central PMCID: PMCPMC7547282.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    Fritz M, Rosolen B, Krafft E, Becquart P, Elguero E, Vratskikh O, et al. High prevalence of SARS-CoV-2 antibodies in pets from COVID-19+ households. One Health. 2021;11:100192. Epub 2020/11/11. doi: 10.1016/j.onehlt.2020.100192. PubMed PMID: 33169106; PubMed Central PMCID: PMCPMC7641531.
    OpenUrlCrossRefPubMed
  19. 19.
    Sit THC, Brackman CJ, Ip SM, Tam KWS, Law PYT, To EMW, et al. Infection of dogs with SARS-CoV-2. Nature. 2020;586(7831):776–8. Epub 2020/05/15. doi: 10.1038/s41586-020-2334-5. PubMed PMID: 32408337; PubMed Central PMCID: PMCPMC7606701.
    OpenUrlCrossRefPubMed
  20. 20.
    Patterson EI, Elia G, Grassi A, Giordano A, Desario C, Medardo M, et al. Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy. Nat Commun. 2020;11(1):6231. Epub 2020/12/06. doi: 10.1038/s41467-020-20097-0. PubMed PMID: 33277505; PubMed Central PMCID: PMCPMC7718263.
    OpenUrlCrossRefPubMed
  21. 21.↵
    Barrs VR, Peiris M, Tam KWS, Law PYT, Brackman CJ, To EMW, et al. SARS-CoV-2 in Quarantined Domestic Cats from COVID-19 Households or Close Contacts, Hong Kong, China. Emerg Infect Dis. 2020;26(12):3071–4. Epub 2020/09/18. doi: 10.3201/eid2612.202786. PubMed PMID: 32938527; PubMed Central PMCID: PMCPMC7706951.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Halfmann PJ, Hatta M, Chiba S, Maemura T, Fan S, Takeda M, et al. Transmission of SARS-CoV-2 in Domestic Cats. N Engl J Med. 2020;383(6):592–4. Epub 2020/05/14. doi: 10.1056/NEJMc2013400. PubMed PMID: 32402157.
    OpenUrlCrossRefPubMed
  23. 23.↵
    Oude Munnink BB, Sikkema RS, Nieuwenhuijse DF, Molenaar RJ, Munger E, Molenkamp R, et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science. 2021;371(6525):172–7. Epub 2020/11/12. doi: 10.1126/science.abe5901. PubMed PMID: 33172935; PubMed Central PMCID: PMCPMC7857398.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    Martina BE, Haagmans BL, Kuiken T, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, et al. Virology: SARS virus infection of cats and ferrets. Nature. 2003;425(6961):915. Epub 1. 2003/10/31. doi: 10.1038/425915a. PubMed PMID: 14586458; PubMed Central PMCID: PMCPMC7094990.
    OpenUrlCrossRefPubMed
  25. 25.
    Ng SK. Possible role of an animal vector in the SARS outbreak at Amoy Gardens. Lancet. 2003;362(9383):570–2. Epub 2003/08/23. doi: 10.1016/S0140-6736(03)14121-9. PubMed PMID: 12932393; PubMed Central PMCID: PMCPMC7134840.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    Lun ZR, Qu LH. Animal-to-human SARS-associated coronavirus transmission? Emerg Infect Dis. 2004;10(5):959. Epub 2004/06/26. doi: 10.3201/eid1005.040022. PubMed PMID: 15216845; PubMed Central PMCID: PMCPMC3323218.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26(7):1033–6. Epub 2020/05/14. doi: 10.1038/s41591-020-0913-5. PubMed PMID: 32398876.
    OpenUrlCrossRefPubMed
  28. 28.↵
    Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–8. Epub 2020/05/01. doi: 10.1038/s41591-020-0897-1. PubMed PMID: 32350462.
    OpenUrlCrossRefPubMed
  29. 29.↵
    Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48). Epub 2020/06/13. doi: 10.1126/sciimmunol.abc8413. PubMed PMID: 32527802; PubMed Central PMCID: PMCPMC7292505.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, et al. Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients. Cell Rep Med. 2020;1(3):100040. Epub 2020/08/25. doi: 10.1016/j.xcrm.2020.100040. PubMed PMID: 32835303; PubMed Central PMCID: PMCPMC7276302.
    OpenUrlCrossRefPubMed
  31. 31.↵
    Desmarets LM, Vermeulen BL, Theuns S, Conceicao-Neto N, Zeller M, Roukaerts ID, et al. Experimental feline enteric coronavirus infection reveals an aberrant infection pattern and shedding of mutants with impaired infectivity in enterocyte cultures. Sci Rep. 2016;6:20022. Epub 2016/01/30. doi: 10.1038/srep20022. PubMed PMID: 26822958; PubMed Central PMCID: PMCPMC4731813.
    OpenUrlCrossRefPubMed
  32. 32.
    Vogel L, Van der Lubben M, te Lintelo EG, Bekker CP, Geerts T, Schuijff LS, et al. Pathogenic characteristics of persistent feline enteric coronavirus infection in cats. Vet Res. 2010;41(5):71. Epub 2010/07/29. doi: 10.1051/vetres/2010043. PubMed PMID: 20663472; PubMed Central PMCID: PMCPMC2939696.
    OpenUrlCrossRefPubMed
  33. 33.↵
    Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. The Lancet Microbe. doi: 10.1016/S2666-5247(20)30172-5.
    OpenUrlCrossRefPubMed
  34. 34.↵
    Addie DD, Jarrett O. Use of a reverse-transcriptase polymerase chain reaction for monitoring the shedding of feline coronavirus by healthy cats. Vet Rec. 2001;148(21):649–53. Epub 2001/06/13. doi: 10.1136/vr.148.21.649. PubMed PMID: 11400984.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    Zhang Q, Zhang H, Gao J, Huang K, Yang Y, Hui X, et al. A serological survey of SARS-CoV-2 in cat in Wuhan. Emerg Microbes Infect. 2020;9(1):2013–9. Epub 2020/09/02. doi: 10.1080/22221751.2020.1817796. PubMed PMID: 32867625; PubMed Central PMCID: PMCPMC7534315.
    OpenUrlCrossRefPubMed
  36. 36.↵
    Liu W, Fontanet A, Zhang PH, Zhan L, Xin ZT, Baril L, et al. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006;193(6):792–5. Epub 2006/02/16. doi: 10.1086/500469. PubMed PMID: 16479513; PubMed Central PMCID: PMCPMC7109932.
    OpenUrlCrossRefPubMed
  37. 37.
    Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357(11):1162–3. Epub 2007/09/15. doi: 10.1056/NEJMc070348. PubMed PMID: 17855683.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    Lin Q, Zhu L, Ni Z, Meng H, You L. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection. J Microbiol Immunol Infect. 2020;53(5):821–2. Epub 2020/04/07. doi: 10.1016/j.jmii.2020.03.015. PubMed PMID: 32249185; PubMed Central PMCID: PMCPMC7141458.
    OpenUrlCrossRefPubMed
  39. 39.↵
    Tang F, Quan Y, Xin ZT, Wrammert J, Ma MJ, Lv H, et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011;186(12):7264–8. Epub 2011/05/18. doi: 10.4049/jimmunol.0903490. PubMed PMID: 21576510.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    Zeng W, Liu G, Ma H, Zhao D, Yang Y, Liu M, et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem Biophys Res Commun. 2020;527(3):618–23. Epub 2020/05/18. doi: 10.1016/j.bbrc.2020.04.136. PubMed PMID: 32416961; PubMed Central PMCID: PMCPMC7190499.
    OpenUrlCrossRefPubMed
  41. 41.↵
    Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–80 e8. Epub 2020/03/07. doi: 10.1016/j.cell.2020.02.052. PubMed PMID: 32142651; PubMed Central PMCID: PMCPMC7102627.
    OpenUrlCrossRefPubMed
  42. 42.↵
    Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–20. Epub 2020/04/01. doi: 10.1038/s41586-020-2180-5. PubMed PMID: 32225176.
    OpenUrlCrossRefPubMed
  43. 43.↵
    Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339–43. Epub 2020/11/08. doi: 10.1126/science.abe1107. PubMed PMID: 33159009; PubMed Central PMCID: PMCPMC7857411.
    OpenUrlAbstract/FREE Full Text
  44. 44.
    Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650–5. Epub 2020/06/24. doi: 10.1126/science.abc6952. PubMed PMID: 32571838; PubMed Central PMCID: PMCPMC7319273.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    Song G, He WT, Callaghan S, Anzanello F, Huang D, Ricketts J, et al. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nat Commun. 2021;12(1):2938. Epub 2021/05/21. doi: 10.1038/s41467-021-23074-3. PubMed PMID: 34011939; PubMed Central PMCID: PMCPMC8134462.
    OpenUrlCrossRefPubMed
  46. 46.↵
    Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell. 2021;184(7):1858–64 e10. Epub 2021/02/26. doi: 10.1016/j.cell.2021.02.010. PubMed PMID: 33631096; PubMed Central PMCID: PMCPMC7871851.
    OpenUrlCrossRefPubMed
  47. 47.↵
    Lee WT, Girardin RC, Dupuis AP, Kulas KE, Payne AF, Wong SJ, et al. Neutralizing Antibody Responses in COVID-19 Convalescent Sera. J Infect Dis. 2021;223(1):47–55. Epub 2020/10/27. doi: 10.1093/infdis/jiaa673. PubMed PMID: 33104179; PubMed Central PMCID: PMCPMC7665673.
    OpenUrlCrossRefPubMed
  48. 48.
    Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956–63. Epub 2020/06/17. doi: 10.1126/science.abc7520. PubMed PMID: 32540903; PubMed Central PMCID: PMCPMC7299280.
    OpenUrlAbstract/FREE Full Text
  49. 49.
    Niu L, Wittrock KN, Clabaugh GC, Srivastava V, Cho MW. A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain. Front Immunol. 2021;12:647934. Epub 2021/05/18. doi: 10.3389/fimmu.2021.647934. PubMed PMID: 33995366; PubMed Central PMCID: PMCPMC8113771.
    OpenUrlCrossRefPubMed
  50. 50.↵
    Zhou Y, Liu Z, Li S, Xu W, Zhang Q, Silva IT, et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 2021;34(5):108699. Epub 2021/01/25. doi: 10.1016/j.celrep.2021.108699. PubMed PMID: 33485405; PubMed Central PMCID: PMCPMC7802522.
    OpenUrlCrossRefPubMed
  51. 51.↵
    Zhu Y, Yu D, Han Y, Yan H, Chong H, Ren L, et al. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals. Sci Adv. 2020;6(45). Epub 2020/10/11. doi: 10.1126/sciadv.abc9999. PubMed PMID: 33036961; PubMed Central PMCID: PMCPMC7673700.
    OpenUrlFREE Full Text
  52. 52.↵
    Lv H, Wu NC, Tsang OT, Yuan M, Perera R, Leung WS, et al. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep. 2020;31(9):107725. Epub 2021/01/28. doi: 10.1016/j.celrep.2020.107725. PubMed PMID: 33500101.
    OpenUrlCrossRefPubMed
  53. 53.↵
    Zhao S, Li W, Schuurman N, van Kuppeveld F, Bosch BJ, Egberink H. Serological Screening for Coronavirus Infections in Cats. Viruses. 2019;11(8). Epub 2019/08/16. doi: 10.3390/v11080743. PubMed PMID: 31412572; PubMed Central PMCID: PMCPMC6723642.
    OpenUrlCrossRefPubMed
  54. 54.
    Deng J, Jin Y, Liu Y, Sun J, Hao L, Bai J, et al. Serological survey of SARS-CoV-2 for experimental, domestic, companion and wild animals excludes intermediate hosts of 35 different species of animals. Transbound Emerg Dis. 2020;67(4):1745–9. Epub 2020/04/18. doi: 10.1111/tbed.13577. PubMed PMID: 32303108; PubMed Central PMCID: PMCPMC7264586.
    OpenUrlCrossRefPubMed
  55. 55.↵
    Deng J, Liu Y, Sun C, Bai J, Sun J, Hao L, et al. SARS-CoV-2 Serological Survey of Cats in China before and after the Pandemic. Virol Sin. 2020. Epub 2020/09/02. doi: 10.1007/s12250-020-00284-5. PubMed PMID: 32870451; PubMed Central PMCID: PMCPMC7459941.
    OpenUrlCrossRefPubMed
  56. 56.↵
    Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr Protoc Microbiol. 2020;57(1):e100. Epub 2020/04/18. doi: 10.1002/cpmc.100. PubMed PMID: 32302069; PubMed Central PMCID: PMCPMC7235504.
    OpenUrlCrossRefPubMed
  57. 57.↵
    Poon LL, Chu DK, Chan KH, Wong OK, Ellis TM, Leung YH, et al. Identification of a novel coronavirus in bats. J Virol. 2005;79(4):2001–9. Epub 2005/02/01. doi: 10.1128/JVI.79.4.2001-2009.2005. PubMed PMID: 15681402; PubMed Central PMCID: PMCPMC546586.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22(22):4673–80. Epub 1994/11/11. doi: 10.1093/nar/22.22.4673. PubMed PMID: 7984417; PubMed Central PMCID: PMCPMC308517.
    OpenUrlCrossRefPubMedWeb of Science
  59. 59.↵
    Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. Mol Biol Evol. 2018;35(6):1547–9. Epub 2018/05/04. doi: 10.1093/molbev/msy096. PubMed PMID: 29722887; PubMed Central PMCID: PMCPMC5967553.
    OpenUrlCrossRefPubMed
  60. 60.↵
    Johari YB, Jaffe SRP, Scarrott JM, Johnson AO, Mozzanino T, Pohle TH, et al. Production of trimeric SARS-CoV-2 spike protein by CHO cells for serological COVID-19 testing. Biotechnol Bioeng. 2021;118(2):1013–21. Epub 2020/11/01. doi: 10.1002/bit.27615. PubMed PMID: 33128388.
    OpenUrlCrossRefPubMed
  61. 61.↵
    Palmer MV, Martins M, Falkenberg S, Buckley A, Caserta LC, Mitchell PK, et al. Susceptibility of white-tailed deer (Odocoileus virginianus) to SARS-CoV-2. J Virol. 2021. Epub 2021/03/12. doi: 10.1128/JVI.00083-21. PubMed PMID: 33692203; PubMed Central PMCID: PMCPMC8139686.
    OpenUrlAbstract/FREE Full Text
  62. 62.↵
    Olival KJ, Cryan PM, Amman BR, Baric RS, Blehert DS, Brook CE, et al. Possibility for reverse zoonotic transmission of SARS-CoV-2 to free-ranging wildlife: A case study of bats. PLoS Pathog. 2020;16(9):e1008758. Epub 2020/09/04. doi: 10.1371/journal.ppat.1008758. PubMed PMID: 32881980; PubMed Central PMCID: PMCPMC7470399.
    OpenUrlCrossRefPubMed
  63. 63.
    Dominguez SR, O’Shea TJ, Oko LM, Holmes KV. Detection of group 1 coronaviruses in bats in North America. Emerg Infect Dis. 2007;13(9):1295–300. Epub 2008/02/07. doi: 10.3201/eid1309.070491. PubMed PMID: 18252098; PubMed Central PMCID: PMCPMC2857301.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.
    Misra V, Dumonceaux T, Dubois J, Willis C, Nadin-Davis S, Severini A, et al. Detection of polyoma and corona viruses in bats of Canada. J Gen Virol. 2009;90(Pt 8):2015–22. Epub 2009/04/10. doi: 10.1099/vir.0.010694-0. PubMed PMID: 19357225.
    OpenUrlCrossRefPubMedWeb of Science
  65. 65.↵
    Osborne C, Cryan PM, O’Shea TJ, Oko LM, Ndaluka C, Calisher CH, et al. Alphacoronaviruses in New World bats: prevalence, persistence, phylogeny, and potential for interaction with humans. PLoS One. 2011;6(5):e19156. Epub 2011/05/19. doi: 10.1371/journal.pone.0019156. PubMed PMID: 21589915; PubMed Central PMCID: PMCPMC3093381.
    OpenUrlCrossRefPubMed
  66. 66.↵
    Griffin BD, Chan M, Tailor N, Mendoza EJ, Leung A, Warner BM, et al. SARS-CoV-2 infection and transmission in the North American deer mouse. Nat Commun. 2021;12(1):3612. Epub 2021/06/16. doi: 10.1038/s41467-021-23848-9. PubMed PMID: 34127676; PubMed Central PMCID: PMCPMC8203675.
    OpenUrlCrossRefPubMed
  67. 67.↵
    Rattanapisit K, Shanmugaraj B, Manopwisedjaroen S, Purwono PB, Siriwattananon K, Khorattanakulchai N, et al. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana. Sci Rep. 2020;10(1):17698. Epub 2020/10/21. doi: 10.1038/s41598-020-74904-1. PubMed PMID: 33077899; PubMed Central PMCID: PMCPMC7573609.
    OpenUrlCrossRefPubMed
  68. 68.↵
    Chandler JC, Bevins SN, Ellis JW, Linder TJ, Tell RM, Jenkins-Moore M, et al. SARS-CoV-2 exposure in wild white-tailed deer (Odocoileus virginianus). Proc Natl Acad Sci U S A. 2021;118(47). Epub 2021/11/05. doi: 10.1073/pnas.2114828118. PubMed PMID: 34732584.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    Kuchipudi SV, Surendran-Nair M, Ruden RM, Yon M, Nissly RH, Nelli RK, et al. Multiple spillovers and onward transmission of SARS-CoV-2 in free-living and captive white-tailed deer. bioRxiv. 2021:2021.10.31.466677. doi: 10.1101/2021.10.31.466677.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    Xiaojie S, Yu L, Lei Y, Guang Y, Min Q. Neutralizing antibodies targeting SARS-CoV-2 spike protein. Stem Cell Res. 2020;50:102125. Epub 2020/12/21. doi: 10.1016/j.scr.2020.102125. PubMed PMID: 33341604; PubMed Central PMCID: PMCPMC7737530.
    OpenUrlCrossRefPubMed
Back to top
Posted December 20, 2021.
Download PDF
Email
Evidence for a Potential Pre-Pandemic SARS-like Coronavirus Among Animals in North America
Trevor J. Hancock, Peyton Hickman, Niloo Kazerooni, Melissa Kennedy, Stephen A. Kania, Michelle Dennis, Nicole Szafranski, Richard Gerhold, Chunlei Su, Tom Masi, Stephen Smith, Tim E. Sparer
bioRxiv 2021.12.17.473265; doi: https://doi.org/10.1101/2021.12.17.473265
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area